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Learning Objectives
• To understand the clinical aspects of HDR brachytherapy, including common clinical indications, patient selection, and evolving evidence in support of this therapeutic modality • To review current prominent clinical trials for HDR brachytherapy 
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Broad Use of HDR Brachytherapy
• Current evidence supports HDR brachytherapy for nearly all brachytherapy indications: • Common indications in practice:
-GYN (cervical, uterine, vaginal, vulvar) -Prostate (monotherapy or boost) -Breast (accelerated partial breast irradiation) -Sarcoma (boost or monotherapy) -Skin (definitive)
• Less common indications: penile, head and neck, rectal, esophagus, bronchial, intraoperative, other • Evidence in development for many indications where HDR is nearly fully established (e.g., breast and prostate)
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Brief Review of Common Indications 
• HDR regimens with 45 Gy in 25 fractions:
-4 x 7 Gy; 5 x 6 Gy; 6 x 5 Gy; 5 x 5.5 Gy 
APBI Technical Guidelines
• 34 Gy in 10 fractions twice daily • PTV_Eval:
-D90% ≥ 90% -V150 < 50 cm 3 ; V200 < 10 cm 3
• Skin dose < 145% of prescription
ABS Consensus Statement 2013, Brachytherapy
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Notable APBI Clinical Trials
• NSABP B-39:
-Randomized trial of WBI vs APBI for Stage 0-2 breast cancer after lumpectomy (≤ 3.0 cm) -3DCRT and brachytherapy (interstitial or intracavitary) permitted -Primary results pending, high rate of 3DCRT
• Multilumen balloon overnight trial (Khan et al):
-4 x 7 Gy; 3 x 8.25 Gy; 2 x 10.5 Gy -Ongoing (Khan et al, Oncology 2013)
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Breast APBI
• Results of B-39 pending -My own prediction is that HDR will likely survive even if APBI inferior to whole breast RT
• Shorter fractionation schedules appealing, trials ongoing • Evidence base growing
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Prostate HDR Brachytherapy
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Prostate HDR Selection Criteria 
Prostate HDR -Prescription Details
• Monotherapy: 13.5 Gy x 2 fractions (NCCN)
• Boost: 9.5-11.5 Gy x 2 fractions; 5.5-7.5 Gy x 3 fractions; 4.0-6.0 Gy x 4 fractions (NCCN) • Technical Details (per RTOG 0924):
-Transrectal u/s guidance -≥ 14 treatment catheters -Active dwells only within PTV -V75% < 1cc for bladder and rectum -Urethra: V125% < 1cc; V150% = 0 cc; D10 < 118% -PTV: V100% ≥ 90% -TRUS based HDR delivered with TRUS probe in patients so dosimetry accurate 
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Prostate HDR
• Data increasing for monotherapy -Data maturing for shorter schedules (e.g., 19 Gy x 1) -Current evidence strongest for: 9.5 Gy x 4 fractions -NCCN: 13.5 Gy x 2 fractions
• Trend towards shorter schedules for boost therapy -15 Gy x 1 was chosen for RTOG 0924
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Prostate HDR vs LDR
• HDR better for very large glands (> 60 cc)
• HDR okay for TURP defects • HDR has potential to be cost effective • Accuracy and optimization may be improved since source is afterloaded after needle placement -Needle migration is a concern
• But…LDR is a single episode of care
Image Guided HDR Brachytherapy
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Image-guided HDR Brachytherapy
• Imaging increasingly used for applicator placement and 3D treatment planning • MRI target definition and planning increasingly common for cervical cancer and prostate • 3D treatment planning permits volume-based prescriptions and planning constraints (vs. pointbased) • Image-guidance may introduce time delays and more steps/locations that must be considered 
Answer
• 13.5 Gy x 2 fractions is the fractionation schedule cited in the current NCCN guidelines. Note that this is 1 additional insertion beyond that required for LDR monotherapy.
• Reference: NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer. Version 2.2014.
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Which of the following statements is true regarding comparisons of HDR versus LDR brachytherapy for locally advanced cervical cancer?
1. HDR and LDR brachytherapy have not been directly compared in any prospective clinical trials. 2. There are no significant differences in tumor control or treatment related complications with the exception of a slight increase in small bowel complications with HDR 3. HDR brachytherapy has inferior local tumor control compared to LDR brachytherapy. 4. HDR brachytherapy has similar tumor control rates, but dramatically worse outcomes for rectum, bladder and small bowel complications. 5. LDR is better than HDR in all aspects that have been compared. 
Answer
• There are no significant differences in tumor control or treatment related complications with the exception of a slight increase in small bowel complications with HDR. The Cochrane Database review recommends HDR based on these findings and the additional advantages of HDR brachytherapy (outpatient, immmobilization, etc).
• Reference: Wang et al., High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (Review). Cochrane Library 2010
